在卡塔尔的复发性多发性硬化症的管理中使用克拉德里宾片的现实世界经验
Beatriz Garcia Cañibano1, Lina Okar2, Yahya Zakarya Baniamer1
1Neurosciences Institute - Hamad Medical Corporation, Doha, Qatar.
Clinical neurology and neurosurgery
|October 30, 2024
概括
克拉迪片 (CladT) 在现实环境中显示出在治疗复发性多发性硬化症 (RMS) 中显著的有效性和安全性. 这项研究支持早期使用CladT治疗RRMS,无论之前的治疗方法如何.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 复发性多发性硬化症 (RMS) 需要有效和安全的治疗选择.
- 克拉迪片 (CladT) 提供了一种有针对性的方法来管理MS.
- 现实世界的数据对于了解临床试验之外的治疗结果至关重要.
研究的目的:
- 评估克拉迪宾片 (CladT) 在复发性多发性硬化症 (RMS) 患者的30个月安全性和有效性.
- 评估CladT在卡塔尔的现实环境中的表现.
- 分析结果,无论之前的疾病修饰疗法 (DMT).
主要方法:
- 从2018年1月到2023年2月进行的回顾性,单中心的观察性研究.
- 包括46名患有RMS的患者,他们至少接受了一次CladT疗程.
- 收集临床数据,MRI发现,淋巴细胞计数和不良事件 (AE).
主要成果:
- 年度复发率 (ARR) 显著降低,从基线1.02降至治疗后0.1或更低.
- 在治疗后,高比例的患者没有复发 (87.5-100%) 和新的Gd+MRI病变 (78-100%).
- 克拉德T表现出良好的安全性,主要是轻度不良事件,没有严重病例;在5名患者中观察到3级淋巴缺血症.
结论:
- 克拉迪片 (CladT) 是有效和安全的管理复发性多发性硬化症 (RMS) 在现实世界中设置.
- 治疗结果与之前的DMT暴露无关,结果一致.
- 这些发现支持在RRMS管理中早期使用CladT.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
147
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
147
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K


